Source comparison
Growth Hormone Secretagogue Peptides: Research Application Comparison
Before selecting a growth hormone secretagogue for your research protocol, understanding the pharmacological trade-offs between peptide classes is essential—not all secretagogues are interchangeable, and the choice determines study feasibility, endpoint reprod
This comparison does not assign a generated winner or score.
- Before selecting a growth hormone secretagogue for your research protocol, understanding the pharmacological trade-offs between peptide classes is essential—not all secretagogues are interchangeable, and the choice determines study feasibility, endpoint reproducibility, and interpretability of results.
- Ipamorelin
- GHS-R1a
- ~2 hours
- Moderate (4–6× baseline)
- None
- Gold standard for clean GH pulsatility studies; ideal for protocols requiring multiple daily doses without cortisol/prolactin interference
- Minimal—no ACTH or prolactin elevation
- Best all-purpose secretagogue for metabolic research; selectivity eliminates confounding variables that plague GH studies
- Hexarelin
- Very High (8–12× baseline)
- Moderate
- Short-duration studies (<6 weeks) where maximum GH amplitude is required
- Receptor desensitization after 8–12 weeks; dose-dependent cortisol elevation at >200 mcg/kg
- Most potent GH secretagogue available, but tolerance limits chronic use; reserve for acute intervention studies
- GHRP-2
- High (6–8× baseline)
- Studies requiring robust GH pulses where appetite stimulation is not a confound
- Mild cortisol and prolactin elevation at higher doses
- Balanced potency and tolerability; useful when Hexarelin's desensitization is a concern but Ipamorelin's amplitude is insufficient
- Sermorelin
- GHRH-R
- ~30 min
- Moderate (3–5× baseline)
- GHRH pathway research; synergistic protocols when combined with GHRPs
- None—cAMP pathway is distinct from ghrelin signaling
- Excellent for dual-pathway studies; short half-life requires 2–3 daily doses to sustain effect
- CJC-1295 No DAC
- GHRH analog with improved stability; standard GHRH component in combination stacks
- Functionally identical to Sermorelin but with better reconstituted peptide stability (21 days vs 14 days at 2–8°C)
- CJC-1295 With DAC
- 6–8 days
- Low continuous elevation
- Chronic IGF-1 elevation studies; once-weekly dosing protocols
- Sustained receptor occupancy can reduce pulsatility and blunt natural circadian GH rhythm
- Only secretagogue suitable for true once-weekly dosing; eliminates pulsatility, making it unsuitable for studies where GH pulse architecture matters
- Tesamorelin
- ~40 min
- Moderate (4–5× baseline)
- Visceral fat reduction research; FDA-approved analog with clinical precedent
- Minimal—most studied GHRH analog in human trials
- Best choice when replicating clinical visceral adiposity protocols; longer half-life than Sermorelin reduces dosing frequency
- MK-677
- 4–6 hours
- Sustained elevation (24h)
- High
- Oral administration studies; aging and sarcopenia models requiring long-duration GH elevation
- Appetite stimulation increases food intake 20–30% in ad libitum models; requires controlled feeding
- Only orally bioavailable secretagogue; eliminates injection compliance issues in long-term studies but appetite effect is unavoidable
- The single most common study design error we observe is selecting a secretagogue based solely on GH pulse amplitude without considering off-target effects or desensitization kinetics. A protocol that uses Hexarelin for 16 weeks will produce beautiful GH elevations for the first 6 weeks—then progressive blunting that researchers often misinterpret as model tolerance when it is actually receptor downregulation specific to that compound. Ipamorelin does not produce this pattern even at 24 weeks, which is why it remains the default choice for chronic GH research despite lower peak amplitude.
- When synergy is the objective, pairing a GHRH analog (CJC-1295 No DAC or Sermorelin) with a GHRP (Ipamorelin or GHRP-2) is the only evidence-supported approach—the two pathways converge at GH vesicle exocytosis but activate through distinct second messengers (cAMP vs calcium). The result is supra-additive GH release that neither compound produces alone. Our Tesamorelin/Ipamorelin stack and CJC-1295/Ipamorelin 5mg/5mg products are pre-mixed in molar ratios optimized for this synergy—eliminating the need for researchers to calculate reconstitution volumes for dual-peptide protocols.